Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 05/22/20

Recent Research Spotlights

Selected CTEP Accomplishments – April 2020

How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find Out

Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer

At NCI, A Robust and Rapid Response to the COVID-19 Pandemic

NCI statement on clinical trials during COVID-19 pandemic

In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1

Immunotherapy Drug Improves Outcomes for Some Children with Relapsed Leukemia

Surgery for Recurrent Ovarian Cancer Does Not Improve Survival

Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from Chemo

For Children with Neuroblastoma, Trial Results Highlight Continued Evolution of Treatment

Study Quantifies Impact of NCI-sponsored Trials on Clinical Cancer Care

FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type

Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer

Study Tests Immunotherapy in People with Cancer and Autoimmune Diseases

Can Some Women Treated for Endometrial Cancer Forgo Radiation after Surgery?

Pediatric MATCH Study Finds More Targetable Genetic Changes than Expected

New Drugs, New Side Effects: Complications of Cancer Immunotherapy

Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests

Making Cancer Clinical Trials Available to More Patients

Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults

Whole- and Partial-Breast Radiation Effective at Preventing Breast Cancer from Returning

Olaparib after Initial Treatment Delays Ovarian Cancer Progression